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Abstract
Histidine decarboxylase (HDC), the unique enzyme responsible for histamine generation, is highly
expressed in myeloid cells but its function is poorly understood. Here, we show that Hdc knockout
mice exhibit a markedly increased rate of colon and skin carcinogenesis. Using Hdc-EGFP BAC
transgenic mice, we demonstrate that Hdc is expressed primarily in CD11b+Ly6G+ immature
myeloid cells (IMCs) that are recruited early on in chemical carcinogenesis. Transplant of Hdcdeficient bone marrow to wildtype recipients results in increased CD11b+Ly6G+ cell mobilization
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and reproduces the cancer susceptibility phenotype. In addition, IMCs from Hdc knockout mice
promote the growth of cancer xenografts and colon cancer cells downregulate Hdc expression
through promoter hypermethylation and inhibits myeloid cell maturation. Exogenous histamine
induces the differentiation of IMCs and suppresses their ability to support the growth of
xenografts. These data indicate key roles for Hdc and histamine in myeloid cell differentiation,
and CD11b+Ly6G+ IMCs in early cancer development.

Keywords
histidine decarboxylase (HDC); histamine; immature myeloid cells (IMCs); tumor-associated
neutrophils (TANs); inflammation; carcinogenesis; receptor for advanced glycation end product
(RAGE)
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Accumulating evidence suggests that myeloid cells are a major component of the tumor
mass and play a pivotal role in promoting tumor progression 1–4. In the bone marrow,
CD11b+Gr-1+ immature myeloid cells (IMCs) are thought to represent myeloid precursor
cells5. However, the myeloid lineage includes both monocytic cells, such as tumorassociated macrophages (TAMs)4, as well as granulocytic cells. It is also increasingly
recognized that tumorigenesis in mice is associated with the recruitment of CD11b+Ly6G+
tumor-associated neutrophils (TANs) that consist of two polarized phenotypes: N1 TANs
that have hypersegmented or lobulated nuclei and are cytotoxic to tumor cells, and N2 TANs
that exhibit circular or ovoid nuclei similar to immature neutrophils of bone marrow and are
protumorigenic 6,7. N2 TANs support tumor growth by producing nitric oxide, angiogenic
factors and matrix-degrading enzymes 8. TGF-β appears to promote N2 polarization6, and
these cells then contribute to suppression of antitumor immune responses 9 and promotion
of metastatic behavior 10.

Author Manuscript

Most TANs are CD11b+Ly6G+, and thus are classified as a subset of CD11b+Gr-1+ cells,
which also include myeloid-derived suppressor cells (MDSCs), a heterogeneous population
of myeloid cells in mice that are excessively produced in cancer. MDSCs can be detected in
the circulation in cancer patients and accumulate in larger numbers in the spleen of cancerbearing mice 11–13. MDSCs include both monocytic (Ly6G−Ly6Chigh) and granulocytic
(Ly6G+Ly6Clow) cells 14, with the latter sharing cell surface markers similar to TANs.
However, MDSCs are defined functionally by their ability to suppress T cell responses 15,
and recent studies have suggested that the functional MDSCs are CD11b+CD49d+ and
monocytic (CD11b+Ly6C+)16. CD11b+Gr-1+ immature myeloid cells can be detected in the
bone marrow and occasionally in the spleen of cancer-free animals11, raising a number of
questions regarding the origins of TANs and MDSCs, and the role of IMCs in early stages of
tumorigenesis6,14.
Histamine is a biogenic amine that has well defined roles in allergic responses and gastric
acid secretion, and has also been linked to the modulation of immune responses. For
example, histamine has been shown to regulate T cells, enhancing Th1-type responses
through the H1-receptor and downregulating both Th1 and Th2 type responses through the
H2-receptor 17. Furthermore, histamine is believed to play an immune regulatory function in
myeloid cells 18,19,20. Histamine can be taken up in the diet, but endogenous histamine is
Nat Med. Author manuscript; available in PMC 2011 July 01.
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generated through conversion of L-histidine to histamine by the action of a unique enzyme,
histidine decarboxylase (HDC). Although mast cells are known to store histamine, recent
studies have suggested that other types of myeloid cells may be important sources of
histamine production 21,22. In mouse models of atherosclerosis, Hdc-expressing myeloid
cells are primarily bone marrow derived and appear more like monocytic precursors rather
than mature macrophages 23. Knockout of the Hdc gene has been reported24,25,26, but
little is known regarding the role of histamine in carcinogenesis. Although patients with
atopic allergy and excessive histamine release are reported to have a reduced incidence of
cancer, the mechanisms remain unclear27,28. Here, we report Hdc is primarily expressed in
CD11b+Ly6G+ IMCs within the bone marrow, where it promotes myeloid cell
differentiation and suppresses cancer formation.

RESULTS
Author Manuscript

Hdc−/− mice exhibit susceptibility to colon and skin carcinogenesis

Author Manuscript

Histamine–deficient Hdc knockout (Hdc−/−) and wildtype mice were injected
intraperitoneally with one dose of a genotoxic colonic carcinogen, azoxymethane (AOM),
followed by 10 days of a non-genotoxic carcinogen, dextran sodium sulfate (DSS) oral
exposure29. While both sets of mice developed colonic tumors, Hdc−/− mice exhibited
significantly greater colorectal tumor number and size compared to wildtype mice (Fig. 1a,
b). Pathological analysis revealed that wildtype mice exhibited low-grade dysplasia and
tubular adenoma with scattered goblet cells, whereas Hdc−/− mice showed high-grade
dysplasia, intramucosal carcinoma and invasive adenocarcinoma with rare goblet cells (Fig.
1c and Supplementary Fig. S1a), along with a greater degree of inflammatory infiltrate and a
significant increase in proinflammatory cytokines IL-1α, IL-1β, and IL-6 (Supplementary
Fig. S1b, c). Tumors from the Hdc−/− mice showed abundant nuclear staining for betacatenin, which was less often present in tumors from wildtype mice (Supplementary Fig.
S1f).

Author Manuscript

To extend these observations, we employed the 2-stage inflammation-associated skin
carcinogenesis protocol using 9, 10-dimethyl-1, 2-benzanthracene (DMBA) and 12-Otetradecanoylpherorbol 13-acetate (TPA). Hdc−/− mice first developed microscopic skin
papillomas 10 weeks after TPA promotion, followed by macroscopic skin tumors 4 months
later. The number, size and rate of the skin tumors in Hdc−/− mice were significantly greater
than in wildtype mice (Fig. 1d, e). Histological analysis revealed that most of lesions were
predominantly composed of benign papillomas; however, some of the skin tumors in Hdc−/−
mice progressed to cancer (Fig. 1f). There was a greater number of infiltrating inflammatory
cells and increased expression of proinflammatory cytokines IL-1α and IL-6 in Hdc−/−
animals (Supplementary Fig. S1d, e). Taken together, these carcinogenesis studies suggest
that Hdc and histamine likely play a protective role in inflammation-associated cancer.
Hdc is expressed primarily in CD11b+Ly6G+ immature myeloid cells
To determine the source of Hdc responsible for the protection against cancer, we generated
an Hdc-EGFP BAC transgenic reporter mouse using a previously published EGFPcontaining cassette30 (Supplementary Fig. S2a). EGFP fluorescence was observed in a

Nat Med. Author manuscript; available in PMC 2011 July 01.
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variety of adult tissues, consistent with previous reports of endogenous Hdc expression 31–
33. In the gastrointestinal tract, EGFP fluorescence was detectable in enteroendocrine cells
at the base of the gastric oxyntic glands, while rare EGFP+ enteroendocrine cells were
apparent in the small intestine and colon, confirmed by staining for E-cadherin and
chromogranin A (Supplementary Fig. S3a). Scattered EGFP+ cells were seen in the dermis
of the skin and connective tissue layer of the lung, and numerous EGFP+ cells were
distributed in the red pulp of the spleen. Consistent with earlier literature, marked EGFP
fluorescence was found in the ventral hypothalamus (Supplementary Fig. S2b).

Author Manuscript
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Although for many years mast cells were postulated to be the major histamine-releasing
cells in the intestine and other organs, immunostaining for tryptase confirmed that the
majority of EGFP+ cells in the intestine, peritoneum and bone marrow were not mast cells
(Supplementary Fig. S3c–f). Immunostaining also confirmed that the vast majority of c-Kit+
mast cells in the dermis of TPA treated Hdc-EGFP mice, and in the colonic tumor stroma of
AOM + DSS treated Hdc-EGFP mice, showed no co-localization with EGFP+ cells
(Supplementary Fig. S3g, h). Furthermore, FACS analysis demonstrated suppression of
Hdc-EGFP expression in c-kit+FcεR+ mast cells of the spleen, peritoneum, and IL-3
dependent bone marrow-derived mast cells (Supplementary Fig. S4a, b). Instead, the most
robust site of EGFP expression was found in bone marrow cells. FACS analysis revealed
that 30–40% of bone marrow cells were EGFP+ and thus Hdc-expressing (Fig. 2a). Staining
with antibody to Hdc and RT-PCR analysis (Supplementary Fig. S5a, b) confirmed Hdc
expression in EGFP+ cells, whereas, no detectable Hdc expression was seen in EGFP− cells.
Further FACS analysis showed that the vast majority of EGFP+ cells were of myeloid
lineages, as nearly all of the cells expressed CD11b (~90 %) and Gr-1 (~87%), while they
were generally negative for CD3, CD19, CD34, and Flk-1 (Supplementary Fig. S5c). FACS
data also indicated that EGFP+ cells in the peritoneum were CD11b+ myeloid cells, rather
than c-kit+FcεR+ mast cells (Fig. 2c). Taken together, these data would suggest that
CD11b+Gr-1+ IMCs are the major source of Hdc expression within the bone marrow.

Author Manuscript

CD11b+Gr-1+ IMCs comprise both the Ly6G+ granulocytic and Ly6C+ monocytic subsets.
Using an antibody to Ly6G, we demonstrated that EGFP is highly expressed in ~60% of
CD11b+Ly6Ghigh and ~50% of CD11b+Ly6Gmid subsets than in CD11b+Ly6G− subset
(~10%) (Fig. 2b). Thus, Hdc-EGFP is expressed primarily in CD11b+Ly6G+ myeloid subset
that by cell surface markers shows some similarity to CD11b+Ly6G+ tumor-associated
neutrophils (TANs)6. In addition, we confirmed that Hdc-EGFP was mainly expressed in
CD11b+CD49d− cells (Supplementary Fig. S6a–c), consistent with an immature,
granulocytic phenotype previously shown to lack the ability to suppress T cell
proliferation16. Interestingly, we found EGFP expression markedly decreased in
differentiated granulocytes (neutrophils) derived from EGFP+ CD11b+Ly6G+ cells treated
with granulocyte colony-stimulating factor (G-CSF) (Fig. 2d). Similarly, incubation of either
EGFP+ or EGFP− CD11b+Gr-1+ IMCs with granulocyte-macrophage colony-stimulating
factor (GM-CSF) resulted in differentiation into monocytes, and in the EGFP+ IMCs this
resulted in repression of EGFP expression (Supplementary Fig. S7a). Real-time RT-PCR
result confirmed that Hdc expression was significantly decreased in the differentiated
monocytes/macrophages (Supplementary Fig. S7b). Taken together, the Hdc-EGFP+
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myeloid lineage appears to comprise precursor cells for both the monocytic and granulocytic
lineages, and expression of Hdc is suppressed during in vitro differentiation.
Histamine regulates the differentiation of CD11b+Gr-1+ IMCs

Author Manuscript

The expression of Hdc in IMCs, but not in mature granulocytes and macrophages, suggested
the possibility of a role for histamine in the differentiation of CD11b+Gr-1+ myeloid subsets.
Consequently, we examined the effects on myeloid subsets of histamine in Hdc−/− mice
(Fig. 3a) and the irreversible Hdc inhibitor alpha-fluoromethylhistidine (α-FMH) in
wildtype mice (Supplementary Fig. S8a). FACS analysis revealed that repression of Hdc
function using these two approaches significantly increased the percentage of CD11b+Gr-1+
IMCs in the bone marrow, spleen and peripheral blood. Furthermore, the relative proportion
of the CD11b+Ly6G+ subset was markedly increased in the peripheral blood of Hdc−/− mice,
in particular in AOM + DSS induced colon tumor-bearing Hdc−/− mice (Fig. 3b). The
increased proportion of granulocytic (CD11b+Ly6G+Ly6C−) and CD11b+Ly6G+Ly6C+
IMCs in the spleen and circulation of Hdc−/− mice, and the decreased proportion of
CD11b+Ly6G−Ly6C+ (Fig. 3c), CD11b+Gr-1− (Supplementary Fig. S9a–c) or
CD11b+CD49d+ (Supplementary Fig. S10a) monocytic cells, suggested that histaminedeficiency might inhibit the differentiation of monocytes. In addition, Hdc−/− mice also
showed a reduced circulating level of mature neutrophils (CD11b−Gr-1+), suggesting
histamine-deficiency might block the maturation of granulocytes (Supplementary Fig. S9a,
b, d). In contrast, Complete Blood Count (CBC) of wildtype and Hdc−/− mice showed that
numbers of neutrophils was increased, whereas monocytes exhibited no statistical change
(Supplementary Fig. S8b–d). Thus, automated CBC analysis of neutrophils and monocytes
is not able to distinguish between mature and immature myeloid cells, and the increase in
neutrophils also reflects the increase in immature CD11b+Ly6G+ cells.

Author Manuscript
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To further characterize the effects of histamine, EGFP+ IMCs were isolated from the bone
marrow of Hdc-EGFP mice, and analyzed by FACS following incubation with GM-CSF
alone or GM-CSF plus histamine. GM-CSF incubation induced both CD11b+Ly6G+
granulocytic and CD11b+Ly6C+ monocytic differentiation, and exogenous histamine
promoted the differentiation of the CD11b+Ly6C+ monocytic subset and decreased the
proportion of the CD11b+Ly6G+ granulocytic subset (Fig. 3d). To address further the
hypothesis that histamine regulates the maturation of CD11b+Ly6G+ granulocytes, we
compared the morphologic appearance of splenic CD11b+Ly6G+ granulocytes from Hdc−/−
and wildtype mice. The nuclear morphology of CD11b+Ly6G+ myeloid cells from Hdc−/−
mice was characterized by an ovoid or circular nucleus (N2 phenotype), similar in some
respects to TAN/N26, whereas CD11b+Ly6G+ cells from wildtype mice showed
hypersegmented nucleus typical of mature neutrophils (N1 phenotype) (Supplementary Fig.
S10b).
Hdc-deficiency leads to a marked reduction in histamine production and availability, and
thus we postulated that within the bone marrow histamine acts in an autocrine or paracrine
manner through defined histamine receptors (HRs). We examined HR expression in myeloid
subsets within the bone marrow. Among the four histamine receptors (HR1–4), H1R and
H2R were identified as the predominant receptors in CD11b+Gr-1+IMCs, and H1R was

Nat Med. Author manuscript; available in PMC 2011 July 01.
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highly expressed in CD11b+Ly6C+ monocytic cells (Supplementary Fig. S10c). Staining
with antibodies to H1R or H2R confirmed H1R and H2R protein expression in
CD11b+Ly6G+ and CD11b+Ly6C+ IMCs, and also revealed increased H1R and H2R
expression in weakly fluorescent EGFP+ cells (Supplementary Fig. S10d). In addition, H1Rand H2R- antagonists were both effective (although H1R more so) in inhibiting the
monocytic differentiation of CD11b+Ly6C+ cells from IMCs after histamine plus GM-CSF
treatment (Fig. 3e). Finally, administration of exogenous histamine in Hdc−/− mice
significantly decreased circulating CD11b+Gr-1+ IMCs (Fig. 3f). Taken together, histamine
promotes the differentiation of CD11b+Gr-1+ IMCs and CD11b+Ly6C+ monocytes through
H1R > H2R autocrine and paracrine pathways.
Hdc+ IMCs are recruited to the inflamed tissue and colon tumor setting

Author Manuscript
Author Manuscript

To show that Hdc+ myeloid cells are recruited by carcinogenic stimuli, we examined EGFP
expression in the AOM + DSS mouse model of colon cancer. Twenty weeks following
AOM + DSS treatment, at a time when gross colonic tumors could be observed in most
(80%) AOM + DSS treated Hdc-EGFP mice; there was marked infiltration of EGFP+ cells
in the colonic adenomas compared to only rare submucosal EGFP+ cells in the colons of
control mice (Fig. 4a and data not shown). In the AOM + DSS treated mice, we confirmed
the presence of numerous CD11b+Gr-1+ myeloid cells in the stroma of tumors (Fig. 4a,
bottom). Interestingly, at earlier time points (8 weeks) after AOM + DSS but prior to tumor
development (20 weeks), there was an even greater number of Hdc-EGFP+ myeloid cells
(Fig. 4b). Thus, there is a strong correlation between the early recruitment of EGFP+ IMCs
and tumor development. Consistent with this notion, one or two doses of AOM resulted in
no significant recruitment of EGFP+ cells to the colon and also no induction of cancer (data
not shown), suggesting that the tumor promoter DSS induces cancer in part through IMC
recruitment. Indeed, DSS treatment resulted in significant mobilization of CD11b+Gr-1+
IMCs in the peripheral blood within 4 days, with minimal changes in CD11b+Gr-1−
monocytes or CD11b−Gr-1+ granulocytes (Supplementary Fig. S11a). These EGFP+ cells in
the inflamed mucosa were positive for CD11b- and Gr-1-specific antibodies staining
(Supplementary Fig. S11b).

Author Manuscript

To determine if HDC+ myeloid cells are also present in human colon cancer, we carried out
an immunohistochemical study of human ulcerative colitis (UC, preneoplastic lesion) and
colitis-associated colorectal cancer (CAC). Similar to our mouse models (Supplementary
Fig. S11c), human UC was characterized by a marked infiltration of HDC+ cells that were
largely restricted to CD11b+ cells. Furthermore, in CAC, CD11b+ cells were still extremely
abundant in areas adjacent to the tumor, but showed marked downregulation of HDC and an
immature morphology in tumor (Fig. 4d and Supplementary Fig. S11d). Consistent to the
observation from mouse colon tumors (Supplementary Fig. S3h), HDC+ inflammatory cells
in human CAC are not tryptase+ mast cells (Fig. 4d right).
It has previously been reported that a single application of TPA results in rapid recruitment
of Gr-1+ inflammatory cells and increased Hdc activity in the skin 34,35. Following TPA
treatment, a substantial number of Hdc-EGFP+ cells were recruited to the dermis and
subcutaneous tissue, with a much greater number at 24 h compared to 6 h post treatment
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(Fig. 4e). FACS analysis of circulating cells in the peripheral blood confirmed that
CD11b+Gr-1+ cells are increased ~3.5 fold one day following a single TPA application (data
not shown). More than half of the CD45+ cells in the TPA-treated dermis expressed EGFP
and the vast majority of EGFP+ cells expressed Gr-1 or CD11b (Supplementary Fig. S12a,
b), but did not express tryptase (Supplementary Fig. S12c) and c-kit (Supplementary Fig.
S3g). In addition, bone marrow transplant experiments showed that the EGFP+ cells that
infiltrated the colon (Fig. 4c) and dermis of skin (Supplementary Fig. S12d) were bone
marrow-derived.

Author Manuscript

We next examined gene expression patterns of bone marrow-derived CD11b+Gr-1+ IMCs
and colon tumor associated CD11b+Gr-1+ MDSCs from wildtype and Hdc−/− mice using the
Mouse Array directly after FACS sorting (Gene Expression Omnibus (GEO) database,
Series Accession number is GSE23502). These studies revealed that at baseline Hdc−/− bone
marrow-derived IMCs showed increased inflammatory cytokine (i.e. IL-1) and chemokine
(i.e. CCR-2) expression compared to wildtype IMCs. More importantly, we found that
tumor-associated MDSCs from both wildtype and Hdc−/− mice showed a much greater (5fold) increase in the expression of IL-1 family ligands (IL-1α, IL-1β and IL-18) and IL-6
(Supplementary Table 1), along with overexpression of a number of chemokines and
chemokine receptors, including CXCL-1, CXCL-2, and CCR-2 (Supplementary Table 2),
and adhesion molecules like ICAM-1, VCAM-1, and CD44 (Supplementary Table 3).
IMCs from Hdc−/− mice accelerate tumor growth

Author Manuscript

In order to confirm that loss of Hdc expression specifically in bone marrow cells promotes
tumor growth, we studied wildtype mice reconstituted with either wildtype or Hdc−/− bone
marrow. Mice transplanted with Hdc−/− bone marrow showed greater susceptibility to
carcinogenesis in both the AOM + DSS-induced colon carcinogenesis model (Fig. 5a) and
the DMBA + TPA induced skin carcinogenesis model (data not shown), at a level closer to
that found in Hdc−/− mice. Hdc−/− mice reconstituted with wildtype bone marrow exhibited
reduced susceptibility to colon carcinogenesis compared with Hdc−/− mice (Fig. 5a).

Author Manuscript

To demonstrate that Hdc-expressing CD11b+Gr-1+ or CD11b+Ly6G+ IMCs contribute
directly to tumor growth, we used a xenograft tumor model in which mouse (CT26) colon
cancer cells were injected subcutaneously into NOD-SCID mice with bone marrow-derived
IMCs isolated from wildtype or Hdc−/− mice36. We found that CD11b+Ly6G+ IMCs from
Hdc−/− mice more strongly promoted the growth of CT26 cancer cells compared to the
IMCs of wildtype mice (Fig. 5b and Supplementary Fig. S14). CD11b+Gr-1+ IMCs from
Hdc−/− mice also promoted greater growth of the xenograft tumors than wildtype
CD11b+Gr-1+ IMCs (Supplementary Fig. S13a). Furthermore, we confirmed that bone
marrow-derived Hdc-EGFP+ CD11b+Gr-1+ IMCs can strongly promote the growth of CT26
cancer cells (Supplementary Fig. S13b). In order to confirm that bone marrow-derived IMCs
did not promote tumor growth as a result of immunosuppression, bone marrow-derived
EGFP+ CD11b+Gr-1+ IMCs were incubated with splenic CD4+ T cells. In contrast to splenic
CD11b+Gr-1+ MDSCs that suppressed IFN-γ from T cells, bone marrow-derived IMCs
failed to have this effect (Fig.S13c). Taken together, these data indicate that bone marrow-
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derived CD11b+Gr-1+ and CD11b+Ly6G+ IMCs can directly promote tumor proliferation
independent of effects on T cell suppression.

Author Manuscript

Indeed, the CD11b+Gr-1+ or CD11b+Ly6G+ IMCs from Hdc−/− mice showed much higher
expression levels of pro-inflammatory cytokines, including an 8-fold increase in IL-6 (Fig.
5c, and Supplementary Table 1), compared to those from wildtype mice. Since previous
studies have indicated an important role for IL-6 in colonic carcinogenesis 37,38, we
examined CD11b+Ly6G+ IMCs from bone marrow of IL-6−/− mice. IL-6-deficiency resulted
in significantly less stimulation of xenograft tumor growth compared with wildtype
CD11b+Ly6G+ IMCs, indicating an important role for IL-6 in the promotion of tumor
growth by IMCs (Fig. 5d). In addition, xenograft tumors that were co-implanted with the
EGFP+ CD11b+Gr-1+ IMCs showed much greater neovascularization (Supplementary Fig.
S13b), and the number of vessel branch points was significantly increased in xenograft
tumors implanted with CD11b+Ly6G+ IMCs, an effect that was inhibited by deletion of the
IL-6 gene (Fig. 5e, f and Supplementary Fig. S14, bottom). Finally, xenograft tumors with
EGFP+ CD11b+Gr-1+ IMCs showed greater proliferation, and recruitment of α-SMA+
cancer-associated fibroblasts (Fig. 6a). Colonic adenomas from Hdc−/− mice also showed
much greater α-SMA+ stromal cells compared to wildtype mice (Fig. 6b). Thus, these data
suggest that CD11b+Gr-1+ or CD11b+Ly6G+ IMCs promote the growth of tumors in part
through IL-6 expression and modulation of the tumor microenvironment.
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To further explore the mechanism of CD11b+Gr-1+ IMCs migration and recruitment in
inflamed tissue, circulating EGFP+ CD11b+Gr-1+ IMCs were monitored in real-time using
Intravital confocal microscopy. The ears of Hdc-EGFP and Hdc-EGFP/Hdc−/− mice were
examined 6 h and 24 h following a single application of TPA. Six hours after TPA
stimulation, a large number of EGFP+ inflammatory cells were observed in the dermis
(Supplementary Fig. S15a) and ear vessels (Supplementary video), compared to rare EGFP+
cells in the circulation and tissue of control mice (data not shown).
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The increased recruitment of IMCs in Hdc−/− mice could be related in part to the increased
number of circulating cells or to increased migration in response to the incipient tumor site.
Using immunofluorescence staining and FACS we found that when the same number of
bone marrow-derived Hdc-EGFP+ CD11b+Gr-1+ IMCs from Hdc-EGFP or Hdc-EGFP/
Hdc−/− mice were injected by tail vein into CT26 colon tumor-bearing NOD-SCID mice,
approximately three times more tumor-infiltrating EGFP+CD11b+ cells, CD11b+Gr-1+
IMCs, and F4/80+ macrophages from Hdc−/− mice migrated to the tumor sites versus from
wildtype mice (Supplementary Fig. S15b–d). Recently, a number of ligands for RAGE
(receptor for advanced glycation end production) have been indicated in monocyte and
macrophage recruitment39. To examine the expression of RAGE ligands in DSS-induced
colitis, q-RT-PCR was performed and we detected a significant increase in the expression of
the RAGE ligand S100A8 in colitis tissue (Fig. 6c) and tumors (Fig. 6d). When AOM +
DSS treatment was applied to Rage−/− mice, we observed a significant reduction in
circulating CD11b+Gr-1+ IMCs compared to wildtype mice (Fig. 6e). These data suggest
that Hdc-deficiency increases the activation and recruitment of CD11b+Gr-1+ or
CD11b+Ly6G+ IMCs in response to carcinogenic stimuli, and that bone marrow-derived
IMCs constitute the majority of recruited EGFP+ inflammatory cells in carcinogenesis.
Nat Med. Author manuscript; available in PMC 2011 July 01.
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Given the downregulation of Hdc expression in colitis-associated cancer, we reasoned that
cancer cells might be selectively modulating myeloid cells through repression of Hdc. First,
we confirmed that when CD11b+Ly6G+ or CD11b+Ly6C+ IMCs isolated from Hdc-EGFP
mice were co-cultured under differentiating conditions in vitro with CT26 cancer cells, there
was greater downregulation of Hdc-EGFP expression (Supplementary Fig. S16a, b) along
with a less differentiated nuclear morphology (ovoid or circular nuclei) (Supplementary Fig.
S16c). This appeared to be cancer specific, since CT26 cancer cell suppressed Hdc-EGFP
expression in IMCs to a much greater extent compared to IEC-6 nontransformed intestinal
epithelial cells (Fig. 6f and Supplementary Fig. S16d). Furthermore, the addition of
exogenous histamine to IMCs co-cultured in vitro with CT26 cancer cells was able to
promote the differentiation of these cells (Supplementary Fig. S16c). This was confirmed
through in vivo studies, where exogenous histamine given by i.p. injection inhibited the
promotion of xenograft tumor growth by CD11b+Ly6G+ IMCs from Hdc−/− mice (Fig. 5b).
We demonstrated that Hdc was also downregulated in our xenograft models, by decreased
EGFP expression in the Hdc-EGFP+ CD11b+Gr-1+ IMCs two days following implantation
with CT26 cancer cells in NOD-SCID mice. In contrast, CD11b+Gr-1+ bone marrowderived IMCs from UBC-EGFP mice did not show such loss of EGFP expression when coimplanted with CT26 cancer cells (Supplementary Fig. S17). Previous reports have indicated
that Hdc transcription is largely regulated by promoter CpG methylation40 41, and we found
increased DNA CpG methylation sites in the Hdc promoter region of Hdc-EGFP+
CD11b+Ly6G+ cells following 48 hrs co-culture with CT26 cancer cells (Fig. 6f). In
addition, microarray studies indicated the upregulation of a number of DNA methylation
genes (e.g. Dnmt 3) in tumor-associated MDSCs compared to bone marrow-derived IMCs,
supporting an induction of DNA methylation in IMCs by colonic tumors (Supplementary
Table 4). Overall, these data are consistent with the notion that cancer cells down-regulate
Hdc expression to prevent maturation of myeloid cells, and thus promote tumor growth.

DISCUSSION

Author Manuscript

We show here that the Hdc gene is expressed primarily in bone marrow CD11b+Gr-1+
IMCs, and that these IMCs contribute to the initiation and promotion of cancer. Histamine
appears to be involved in the normal maturation and differentiation of myeloid cells, and a
deficiency in Hdc leads to abnormal myeloid differentiation and the promotion of colonic
and skin carcinogenesis. Cancers appear to mimic locally the Hdc knockout phenotype by
downregulating Hdc expression in nearby myeloid cells through the induction of Hdc
promoter hypermethylation, thereby inhibiting further myeloid differentiation. The increased
carcinogenesis observed in the Hdc−/− mouse was due primarily to Hdc-deficiency in the
bone marrow cells, and was associated with increased recruitment of IMCs to the cancer
sites in a RAGE-dependent manner39. The induction of cancer by IMCs was mediated
through an IL-6-dependent mechanism, since deletion of IL-6 in the IMCs resulted in
inhibition of tumor growth and angiogenesis.
Previously, mast cells were considered the primary source of Hdc since they are known to
store and release histamine. However, our study demonstrates that Hdc is not expressed by
tryptase+ or c-kit+FcεR+ tissue mast cells, but rather by CD11b+Gr-1+ IMCs that constitute
30–40% of bone marrow hematopoietic cells. Hdc expression was largely localized to the
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CD11b+Ly6G+ granulocytic subset within the bone marrow where it appeared to contribute
to myeloid differentiation in a H1R- and H2R- dependent manner. Deletion or inhibition (via
α-FMH) of Hdc resulted in marked abnormalities in myeloid differentiation and decreased
circulating mature granulocytes and monocytes and increased CD11b+Ly6G+ IMCs.
Although these changes were not clearly reflected in automated (coulter) counting of
peripheral leukocytes, the changes were confirmed by both FACS and manual counting of
peripheral smears (not shown). Thus, Hdc+ CD11b+Gr-1+ cells might function as precursors
for both mature neutrophils and monocytes.
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In both our mouse and human studies, we observed that most CD11b+ cells were also HDC+
in preneoplastic tissues, while there was a much lower frequency of HDC+ in CD11b+ cells
in established cancers. Hypermethylation of CpG promoter sites was associated with
downregulation of Hdc expression in Hdc-EGFP+ IMCs co-cultured with colon cancer cells
suggesting that this may be a tumor-induced phenomenon. Cancer cells appear to
epigenetically reprogram myeloid progenitors which might account for the development of
TANs or even MDSCs in the setting of cancer. Indeed, our microarray data showed
substantial differences in gene expression between bone marrow-derived Hdc+
CD11b+Gr-1+ IMCs and tumor-associated MDSCs, including the upregulation of
methylation genes associated with epigenetic reprogramming. Thus, while bone marrowderived Hdc+ CD11b+Gr-1+ (mainly expressing CD11b+Ly6G+) IMCs resemble
superficially MDSCs with respect to surface markers, they are CD11b+CD49d− and not able
to suppress T cell function, and thus are functionally distinct from MDSCs16, and more
closely resemble TANs.
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In early stages of skin and colonic carcinogenesis, Hdc+ IMCs are rapidly recruited to the
sites of carcinogenic stimuli exposure where they contribute to tumor development.
Interestingly, we show here that tumor promoting agents, such as TPA in the skin or DSS in
the colon, work in a large part by mobilizing and recruiting Hdc+ IMCs. Increased cancer
susceptibility in Hdc−/− mice was a general phenomenon mediated largely by Hdcdeficiency in bone marrow cells; while we could not completely exclude a role for non-bone
marrow derived Hdc in our transplants, the evidence for recipient Hdc was related to the
incomplete (~70%) nature of the marrow transplants. The increased cancer was due to an
increase in circulating IMCs, as well as a 3-fold more rapid migration and recruitment of
Hdc−/− IMCs to the cancer site in a RAGE-dependent manner. Hdc−/− IMCs also expressed
increased IL-6 upon LPS stimulation, and knockout of IL-6 in bone marrow IMCs reduced
their ability to promote tumor growth and angiogenesis, consistent with previous studies
37,38. Our findings also point to a direct effect of IMCs on tumor promotion as we found
that in the setting of histamine-deficiency, exogenous histamine partially reversed the
effects. Lack of complete reversal by exogenous histamine is consistent with the previous
findings that in immature mast cells exogenous histamine is unable to completely substitute
for endogenous histamine42.
Growing evidence points to an important role for CD11b+Gr-1+ cells in the cancer
promotion. While cancerous tissues have for many years been known to be histamine rich,
our studies indicates that histamine is derived largely from Hdc+ CD11b+Ly6G+ IMCs. In
previous studies, H2R antagonists have generally not been shown to be effective in the
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treatment of cancer 43–45; this may have been due, in part, to their inhibitory effects on the
differentiation of IMCs. However, further studies are needed to assess the impact on cancer
risk of HR antagonists, particularly H1R antagonists that have not been examined46.
Interestingly, patients with atopic disease, associated with increased histamine secretion,
appear to be less susceptible to carcinogenesis27,28,47,48. This has been attributed to
enhanced immunosurveillance, but given our findings, could also be related to histaminedependent effects on IMCs. Recently, a genetic mutation of HDC leading to loss of function
has been described in association with Tourette’s syndrome, however, the cancer
susceptibility of this family has not been reported26. Overall, our results suggest that the
balance of histamine within the tumor microenvironment may be important, and that
CD11b+Gr-1+ IMCs represent an important therapeutic target for the control of cancer
growth.

Author Manuscript

Gene Expression Omnibus (GEO) database, Series Accession number is GSE23502.

METHODS
Generation of Hdc-EGFP BAC transgenic mice
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The PKD4-NICD-EGFP plasmid was used as a PCR template to amplify a fragment
containing EGFP and 5′ and 3′ ends homologous to sequences flanking the mouse Hdc ATG
(PCR primers: forward 5′GGTCCCTGTGCGCCCCGCCCGGCCCGCAGGCAGCCACCTGGCGAGTCTGACATG
GTGAGCAAGGGCGAGGAGCT-3′, reverse 5′GGCCGGACGCGAACGTGGAGAAGGACGGGAGCAGAGCGTCGCTGACAGCCATT
CCTCCTTAGTTCCTATTCCGA-3′, with the underlined region homologous to the
sequence flanking the Hdc translational start site). The BAC clone (# RP23-474H6 from
CHORI) was introduced into the bacterial strain BL250. BL250 bacteria containing the BAC
RP23-474H6 were made competent and transformed with the amplified fragment by
electroporation according to previously described protocols 30. Clones in which the
amplified fragment was inserted via homologous recombination were selected using
chloramphenicol and Kanamycin resistance cassettes. Selected colonies were screened for
correct recombination by amplification using EGFP- and Hdc-specific primers. The FRTflanked KANA gene was excised from Hdc-EGFP-KANA BAC clones by expressing the
FLP recombinase. CHEF gel electrophoresis and DNA sequencing confirmed correct
transgene construction and integrity of the BAC flanking sequence (data not shown). The
Hdc-EGFP BAC was then purified for pronuclear microinjection. Potential founder mice
(B6/CBA mixed background) were genotyped by tail DNA amplification using primers
specific for the EGFP coding sequence. The founder transgenic mice were then backcrossed
with wildtype C57BL/6 mice.
In some experiments, Hdc-EGFP transgenic mice were crossed to Hdc−/− mice in which
exon 5 of Hdc gene was replaced with a Neomycin cassette24. All the transgenic mice were
housed in micro-isolator, solid-bottomed polycarbonate cages of a pathogen free condition.
All experiments were approved by the Institutional Animal Care and Use Committees of
Columbia University, College of Physicians and Surgeons.
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Antibodies and immunohistochemical staining
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The following antibodies were used in the current studies: Hdc-specific antiserum (EURODIAGNOSTICA); GFP and E-Cadherin-specific antibodies (Invitrogen); antibody to
Chromogranin A (ImmunoStar); antibody to tryptase (abcam); PE-conjugated lineage
specific antibodies (CD3, CD19, CD45, CD49d, and Ly6G), APC-conjugated antibody to
CD11b, PercP-conjugated antibodies to Ly6C and Gr-1 (Ly6G and Ly-6c) (all from BD
Pharmingen). PE-conjugated antibodies CD34, F4/80, and FcεRIα, Pe-cy7-conjugated
antibody to CD117 (c-kit) (all from eBioscience); H1R and H2R-specific antibodies from
Novus Biologicals. Texas Red-conjugated rabbit-specific secondary antibody and Texas redconjugated rat-specific secondary antibody (Vector Laboratories) were used for
immunohistochemistry analysis. Tissue samples from Hdc-EGFP transgenic mice were
fixed with 4% Paraformaldehyde for 12 hours followed by 30% sucrose overnight. EGFP
fluorescence expression was directly observed using an inverted fluorescence microscope
(Nikon Eclipse TE2000-U). Images were analyzed with Adobe Photoshop.
RNA extraction and quantitative RT-PCR analysis
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Total RNA was extracted from tissues of Hdc-EGFP transgenic mice and control mice using
Trizol (Invitrogen). High fidelity cDNA was generated from each RNA samples with
Superscript III cDNA amplification System (Invitrogen). Quantitative RT-PCR reaction
samples were prepared as a mixture with Quantitect SYBR Green PCR kit (Qiagen)
following the manufacturer’s instructions. Reactions were performed using an Applied
Biosystems Prism 9700 PCR machine. The PCR conditions were as follows: 95 °C for 15
min followed by 45 cycles of 95 °C for 15 sec, 55 °C for 30 sec and 72 °C for 30 sec. The
primer sequences used are as shown below: mHdc forward 5′TGCCTGTGTTTGTCTGTGCAACG-3′; reverse 5′ATCTGCCAATGCATGAAGTCCGTG-3′; IL-1α forward 5GAGCGCTCAAGGAGAAGACCAG-3′; reverse 5′CAGGTGCACCCGACTTTGTTCT-3′; I L-1β forward 5′CAAGCAACGACAAAATACCTGTG-3′; reverse 5′AGACAAACCGTTTTTCCATCTTCT-3′; I L-6 forward 5′CCGGAGAGGAGACTTCACAGAG-3′; reverse 5′CTGCAAGTGCATCATCGTTGTT-3′; TNF-α forward 5′TGGCCCAGACCCTCACACTCAG-3′, reverse 5′-ACCCATCGGCTGGCACCACT-3′; T
G F-β forward 5′-ACCGGAGAGCCCTGGATACCA-3′, reverse 5′TATAGGGGCAGGGTCCCAGACA-3′; GAPDH forward 5′CCACTCACGGCAAATTCAAC-3′; reverse 5′-GTAGACTCCACGACATACTCAG-3′.
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Single-cell preparations for FACS analysis and sorting
Bone marrow-derived cells (BMDCs) from the femur and tibia of euthanized mice were
flushed with ice-cold Hanks' Balanced Salt Solution (GIBCO) and depleted of red blood
cells (RBCs) using RBC lysing buffer (BD Biosciences). Total nucleated cells in peripheral
blood were isolated after erythrocyte lysis. Single-cell suspensions were made by filtrating
cells through 40 µm strains. For FACS analysis, single-cell suspensions were stained with
antibodies and evaluated by multi-color flow cytometry using a LSRII flow cytometer (BD

Nat Med. Author manuscript; available in PMC 2011 July 01.

Yang et al.

Page 13

Author Manuscript

Biosciences). Data were analyzed using FlowJo7 software (Tree Star). EGFP-expressing
bone marrow cells and immature myeloid cells (CD11b+Gr-1+ and CD11b+Ly6G+) were
sorted with a FACStarPlus flow cytometer (BD Biosciences). Similar protocols were used
for EGFP+ IMCs from tumors. EGFP+ cells were isolated for in vitro co-culture experiments
and co-implanted with tumor cells in xenograft models.
DSS induced colitis and AOM and DSS induced colonic carcinogenesis models
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According to the protocol previously described, twenty 3-month-old Hdc-EGFP mice were
treated with 3% non-genotoxic agent dextran sodium sulfate (DSS) (MP Biomedical, MW is
36,000 to 50,000) given in the drinking water29. For the acute colitis model, control mice
were treated with distilled water. Colonic tissues and peripheral blood were collected at days
4, 10 and 15. In the AOM + DSS colonic carcinogenesis experiments, control groups
included untreated Balb/C mice, mice injected with a single dose of the genotoxic colonic
carcinogen, azoxymethane (AOM, 12.5 mg kg−1 weight), and mice treated with DSS alone
(10 days); the AOM + DSS group were given one dose of AOM intraperitoneal injection
followed by one cycle of DSS in drinking water for 10 days. 15 weeks (for Balb/C mice)
and 20 weeks (for C57BL/6 mice) later mice were sacrificed; colonic tissue fixed with 4%
PFA and 30% sucrose for frozen tissue or fixed in 10% formalin for paraffin embeddings.
Each group had 8 mice.
TPA induced inflammatory response in the skin and DMBA and TPA induced skin
carcinogenesis model
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Eight 3-month-old Hdc-EGFP mice were treated with 12-O-tetradecanoylpherorbol 13acetate (TPA) (8.5 nmol in 0.2 ml of acetone, P-8139 Sigma) which was painted on the
shaved dorsal skin. Control mice were painted with 0.2 ml of acetone. Animals were
sacrificed by cervical dislocation 6 hours and 24 hours after application of TPA. A piece of
dorsal skin (2.0 × 2.0 cm) was used for histological analysis. In order to develop skin cancer,
wildtype mice and Hdc−/− mice (Balb/C background, each group had 5 mice) were initiated
once with 100 nmol of 9, 10-dimethyl-1, 2-benzanthracene (DMBA, Sigma), following
twice weekly 8.5 nmol TPA treatment. Skin tissue were fixed with 4% PFA and 30%
sucrose for frozen tissue or fixed in 10% formalin for paraffin embeddings.
Intravital microscopy study
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Intravital microscopy of the cutaneous microvasculature of the ear was performed as
described previously 49. Briefly, an acute inflammatory response was induced in the ears of
EGFP-expressing wild type and Hdc−/− mice by application of a single dose of TPA (8.5
nmol, 20 µl per mouse). The number of EGFP-expressing cells that had emigrated from the
blood into the surrounding tissue was determined at 6 and 24 hours after TPA stimulation.
This was accomplished using an Intravital system consisting of a Zeiss Axiotech vario
microscope with a 20 X water-immersion Olympus objective (LUMPlanFl, 0.5 NA), a
Yokogawa CSU-22 spinning disk confocal scanner, a iXON EM camera, and a 488-nm laser
line (Revolution XD, Andor Technology, South Windsor, CT) to detect EGFP-labeled cells.
The extent of cell migration was measured by off-line analysis (ImagePro).
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CT26 mouse colon cancer cells were grown in complete media. Once cells were 70–80%
confluent, cells were washed with sterile PBS 3–4 hours before harvesting in order to
remove dead and detached cells. Trypsin-EDTA was used to detach cells and cells were then
centrifuged at 1200 rpm for 5 min followed by washing twice with PBS. Cells were then
counted using a hemocytometer. Cells were prepared for injection by suspending cells in a
volume so that 100 µl PBS contained 1.0 × 106 cells. Sorted EGFP+ and EGFPCD11b+
Gr-1+ or CD11b+Ly6G+ IMCs were also counted using a hemocytometer. A combination of
100 µl CT26 cells and 100 µl IMCs were then injected subcutaneously (2.0 × 106 cells) into
the two-sides of the lower back of the mice. Exogenous histamine (800 µg kg−1 weight per
day, I.P injection) was administered for 20 days to inhibit xenograft tumor growth. About
21–25 days later, tumors were harvested to measure tumor weight and size. Each group had
6 SCID mice. A similar protocol was used for mouse gastric cancer cells MNK45 and
mouse skin cancer cells TGAC–43 experiment (data not shown).
Immature myeloid cell differentiation studies
EGFP+ and EGFP− IMCs were sorted from the bone marrow and spleen of Hdc-EGFP mice.
Cells were resuspended and IMCs cultured in 6-well plates with 15% FBS RPMI 1640
media. Histamine (5 × 10−7M), H1R antagonist (1 µM pyrilamine maleate, sigma), H2R
antagonist (50 µM cimetidine, sigma), Granulocyte-Macrophage Colony-Stimulating Factor
(GM-CSF) and Granulocyte Colony-Stimulating Factor (G-CSF) were added (final
concentration is 60 ng ml−1) to the media and differentiated myeloid cells harvested at
various time points (24, 48 or 72 hours).
Microarray performance and statistical analysis
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Differentially expressed genes of CD11b+Gr-1+ IMCs were examined by microarray
analysis (Affymetrix Mouse 430.2 array). Total RNA of Hdc-expressing CD11b+Gr-1+
IMCs from the bone marrow was extracted from Hdc-EGFP and Hdc-EGFP/Hdc−/− mice (3
mice in each group). CD11b+Gr-1+ MDSCs of colonic tumors were sorted from 10–12
colon tumors of wildtype and Hdc−/− mice (5 mice in each group) and pooled to extract total
RNA for Microarray studies. RNA concentration and integrity were measured using
standard protocols; cRNA synthesis, labeling, microarray hybridization and scanning were
performed by Columbia University Irving Cancer Center shared Resources, according to the
protocol of Gene CHIP 3’ IVT EXPRESS KIT (AFFYMETRIX 901228). Pooled samples
from each mixture were hybridized to two arrays. Raw CEL files were subjected to an
established battery of quality tests using the Bioconductor package. Arrays were normalized
using GCRMA algorithm. The microarray data were deposited in the GEO database (Gene
Expression Omnibus) (Series Accession number is GSE23502). Differential expression of
four comparisons was evaluated using LIMMA (LInear Models for MicroArrays). Both
Limma and GCRMA are part of the Bioconductor suite which runs in the R statistical
computing environment. The relative expression of an experimental condition (e.g. Hdc
knockout) compared to a control condition (e.g. WT) was expressed as a Log2 ratio. A
statistical significance cutoff of the Benjamini-Hochberg false discovery rate (FDR) ≤ 0.05
was used. Four sets of comparisons were performed to screen the upregulated or
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downregulated genes in the Hdc knockout CD11b+Gr-1+ IMCs or MDSCs (experiment
group) versus the equivalent controls from the WT mice. Set 1: Hdc-expressing
CD11b+Gr-1+ IMCs from the bone marrow of Hdc knockout mice compared to bone
marrow IMCs from WT mice. Set 2: CD11b+Gr-1+ MDSCs in colonic tumors of Hdc
knockout mice compared to WT mice. Set 3: CD11b+Gr-1+ MDSCs from colonic tumors of
WT mice compared to IMCs from WT bone marrow cells. Set 4: CD11b+Gr-1+ MDSCs
from colonic tumors of Hdc knockout mice compared to IMCs from bone marrow cells of
Hdc knockout mice.
Measurement of cytokine levels by ELISA
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CD11b+Gr-1+ IMCs in the bone marrow and spleen of colon tumor-bearing Hdc−/− and
wildtype mice and CD4+ T cells in the spleen were sorted by FACS. 2.5 × 105 IMCs and 2.5
× 105 T cells were cultured in anti-CD3e pre-coated 24-well plates (with Concanavalin A at
5 µg ml−1 of culture medium). The levels of IFN-γ in the supernatant of cells cultured were
determined using ELISA (cat 555138, BD Company, San Diego, CA). Absorbance was
measured at 450 nm by a Multiscan MC reader, and the samples were analyzed by DELTA
SOFT II software (BioMetallics, Inc., Princeton, NJ).
Sodium bisulfite treatment and sequencing analysis
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Bone marrow-derived Hdc-EGFP-expressing CD11b+Ly6G+ IMCs were co-cultured with
CT26 cancer cells for 48 hours. Genomic DNA of IMCs were extracted and subjected to
sodium bisulfite modification (EZ DNA Methylation-Gold Kit, Zymo Research, Orange,
CA) as described previously. After PCR amplification using primers (−800 and +200 bp
from the transcript start site of mouse Hdc gene), the PCR products were cloned into the
TOPO vector. The inserted PCR fragments of the individual clones obtained from each
sample were sequenced with both M13 reverse and M13 forward primers using an ABI
automated sequencer. The primer sequences used are as shown below: Primer 1 forward 5′TAGGAGGAGTAATTTAAGGGAGATGA-3′; reverse 5′AAAAAAAACACCACTAAAACCAAAC-3′; Primer 2 forward 5′TTTGAGTTTAGTTTGGTTAGTTATGG-3′; reverse 5′CAACTATCAACAAAACTTCTTAATC-3′; Primer 3 forward 5′TTTTTAGTTTTGTTTGTTGTAGAAG-3′; reverse 5′ATAAAATTACTCCTACCCTAACTTCTCTAT-3′; Primer 4 forward 5′ATTTGATAAAGTGGTAATTTTTTTTT-3′; reverse 5′AACACTTATTCTAAATTCTTTACCTC-3′.
Statistical Analysis
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Data from at least three independent experiments or five mice per group are represented as
mean ± s.d. Statistical difference between groups was evaluated by Student’s t test. A P
value < 0.05 was considered statistically significant.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Histamine-deficient Hdc−/− mice are highly susceptible to colorectal and skin
carcinogenesis

Author Manuscript

(a) Macroscopic appearance of colorectal tumors from wildtype and Hdc−/− mice. Hdc−/−
mice and wildtype mice (both male Balb/c background) were injected with a single dose of
AOM followed by DSS in the drinking water for 10 days. Fifteen weeks post DSS treatment,
more large colonic tumors were observed in the distal colon and rectum of Hdc−/− mice.
(b) The number of large (diameter > 3mm) and small (diameter < 3mm) colorectal tumors in
Hdc−/− mice versus wildtype mice (* P < 0.05; mean ± s.d. n =8, each group).
(c) Representative haematoxylin-eosin stained colonic tumor sections from wildtype and
Hdc−/− mice (Scale bar, 50 µm).
(d) Macroscopic appearance of the skin tumors from wildtype and Hdc−/− mice. Wildtype
and Hdc−/− mice were treated with the tumor initiator DMBA and then treated twice weekly
with the tumor promoter TPA. Four months following exposure to DMBA + TPA treatment,
a large number of visibly apparent papillomas were seen on the dorsum of Hdc−/− mice.
(e) The number of skin papillomas in Hdc−/− mice versus wildtype mice, including both
large (diameter > 2.5mm) and small (diameter < 2.5mm) papillomas (* P < 0.05; mean ±
s.d. n = 5, each group).
(f) Representative haematoxylin-eosin stained skin tumor sections from wildtype and Hdc−/−
mice (Scale bar, 50 µm).
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Figure 2. CD11b+Ly6G+ IMCs are the predominant source of Hdc-EGFP expression in the bone
marrow

(a) The left panel shows the percentage of EGFP+ cells within the bone marrow (BM),
spleen, and peripheral blood of Hdc-EGFP mice; the right panel shows the relative
proportion of CD11b+ and Gr-1+ cells gated from the EGFP+ subset respectively.
(b) Expression of CD11b+Ly6G+ cells. CD11b+Gr-1+ myeloid cells were gated from the
bone marrow of Hdc-EGFP mice. FACS analysis here indicates the proportion of EGFP+
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cells that were CD11b+Gr-1+Ly6Ghigh, CD11b+Gr-1+Ly6Gmid, and CD11b+Gr-1+Ly6G−
cells. This figure shows representative data from five experiments.
(c) Analysis of peritoneal exudative cells (PECs). Approximately 12% of EGFP+ were
detected in the PEC by FACS. CD11b+Gr-1+ (28%) and CD11b+Gr-1− (47%) myeloid cells
were the major EGFP+ cells. Approximately 15% of EGFP+ cells expressed mast cell
markers: c-kit+FcεR+.
(d) Differentiation of splenic Hdc-EGFP+ IMCs. Immunofluorescence of DAPI stained
EGFP+ CD11b+Ly6G+ IMCs treated with or without G-CSF for 48 hours showed
suppression of EGFP expression with granulocyte differentiation (The pictures show
representative data from three independent experiments).
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Figure 3. Hdc–deficiency upregulates CD11b+Gr-1+ and CD11b+Ly6G+ IMCs

(a) The percentage of CD11b+Gr-1+ IMCs in the BM, spleen, and peripheral blood in
wildtype and Hdc−/− mice were measured by FACS analysis (* P < 0.05; mean ± s.d. n = 10,
each group).
(b) The relative proportion of CD11b+Ly6G+ cells in the peripheral blood and spleen of
wildtype and Hdc−/− mice, with and without AOM + DSS-induced colon tumors, as
measured by FACS analysis (* P < 0.05; ** P < 0.01; mean ± s.d. n = 5, each group).
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(c) FACS analysis shows the abundance of the Ly6G and Ly6C subsets in CD11b+ cells in
the peripheral blood (top) and spleen (bottom) of wildtype (left) and Hdc−/− (right) mice.
The figure is representative of data from five mice of each group.
(d) Differentiation of IMCs. In vitro incubation of BM-derived EGFP+ CD11b+Gr-1+ IMCs
with GM-CSF and histamine followed by FACS analysis for Ly6G and Ly6C surface
expression. The figure is representative of data from three independent experiments.
(e) Histamine receptor blockade inhibits CD11b+Ly6C+ monocyte differentiation.
CD11b+Gr-1+ IMCs sorted from the BM of Hdc−/− mice were incubated with histamine,
GM-CSF, histamine and GM-CSF, histamine, GM-CSF, and H1R antagonist, histamine,
GM-CSF, and H2R antagonist, or histamine, GM-CSF, H1R, and H2R antagonists,
respectively. The proportion of CD11b+Ly6C+ monocytes was then assessed by FACS
analysis (* P < 0.05; ** P < 0.01; Student’s t test. The figure shows the mean ± s.d. from
three independent experiments).
(f) Effect of exogenous histamine on circulating CD11b+Gr-1+ IMCs in Hdc−/− mice. The
percentage of CD11b+Gr-1+ IMCs by FACS in the peripheral blood of wildtype, Hdc−/−,
and Hdc−/− mice treated with exogenous histamine (* P < 0.05; mean ± s.d. n = 5, each
group).
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Figure 4. EGFP+ IMCs are recruited to the inflamed tissue and increased in colonic
carcinogenesis

(a) Immunofluorescence and H&E sections from AOM + DSS–treated (20 weeks) and
control Hdc-EGFP mice (n = 5). Top: Rare submucosal EGFP+ cells were observed in the
colon of control mice, whereas, a large number of EGFP+ cells were observed in the colonic
adenomas of AOM + DSS–treated mice. H&E staining of colonic tumors confirmed
abundant inflammatory cells in the stroma. Bottom: Immunostaining of serial sections
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demonstrates that EGFP+ cells are Hdc+ and approximately 50% of CD11b+ and Gr-1+ cells
are EGFP+.
(b) Left: Immunofluorescence image showing EGFP+ cells in the DAPI-stained colon of
Hdc-EGFP mice treated with DSS (10 days). Right: Immunofluorescence image showing a
greater number of EGFP+ cells in the DAPI-stained colon of Hdc-EGFP mice 8 weeks
following AOM + DSS treatment. (i.e. compared to Fig. 4a, prior to tumor development)
(c) Immunofluorescence image of DAPI–stained colon from BM transplanted mice 10 days
post DSS showing that infiltrating EGFP+ cells are BM–derived (donor: Hdc-EGFP mice;
recipient: wildtype B6 mice).
(d) Immunofluorescence stained human colonic Inflammatory Bowel Disease (IBD) and
colitis-associated carcinoma tissue sections showing HDC (green), CD11b (red) or tryptase
(red). White arrows show HDC+ cells (which all co-localize with CD11b+ cells in IBD
tissue); while red arrows show cells that express CD11b or tryptase alone. The figure is
representative of data from analysis of five IBD and five cancer samples.
(e) Immunofluorescence and H&E stained sections show the presence of inflammatory cells
and EGFP+ cells in the skin following a single TPA treatment. Top: H&E stained skin
sections. Bottom: Immunofluorescence shows a large number of EGFP+ inflammatory cells
in the dermis 24 hours following TPA treatment, compared to 6 hours following TPA
treatment or acetone treated controls (n = 5).
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Figure 5. Bone marrow derived IMCs from Hdc−/− mice accelerate tumor growth

(a) Colonic tumor numbers in BM transplanted mice at 20 weeks following AOM + DSS.
Wildtype and Hdc−/− mice were lethally irradiated and reconstituted with wildtype or Hdc−/−
bone marrow (n = 6, * P < 0.05 compared to indicated control).
(b) Xenograft tumor weight. CT26 colon cancer cells were implanted in NOD-SCID mice
alone (control) or with CD11b+Ly6G+ BM-derived IMCs from wildtype mice, or Hdc−/−
mice, with or without exogenous histamine (800 µg kg−1 weight per day, I.P injection) (* P
< 0.05; ** P < 0.01; mean ± s.d. n = 7, each group).
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(c) Cytokine expression levels in BM-derived IMCs. Messenger RNA expression of IL-1α,
IL-1β, IL-6, Tgf-β, and Tnf-α in CD11b+Ly6G+ IMCs from Hdc−/− mice compared to IMCs
from wildtype mice were analyzed by Q-RT-PCR.
(d) Effect of IL-6 deficiency on induction of tumor xenograft growth by IMCs.
CD11b+Ly6G+ bone marrow IMCs isolated from IL-6−/− mice exhibited suppression of
CT26 cancer cells when implanted into NOD-SCID mice alone (control) or with
CD11b+Ly6G+ bone marrow IMCs from wildtype or IL-6−/− mice. Tumor weight was
measured (* P < 0.05; mean ± s.d. n = 7).
(e) and (f) The number of vessel branch points in xenograft tumors were counted in
xenograft tumors derived from CT26 cancer cells injected with no CD11b+Ly6G+ IMCs
(Control) or IMCs from wildtype mice, Hdc−/− mice, Hdc−/− cells + histamine, or IL-6−/−
mice (* P < 0.05; mean ± s.d. n = 7, each group).
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Figure 6. Migration of circulating CD11b+Gr-1+ IMCs is RAGE-dependent and suppression of
Hdc occurs through a methylation-dependent mechanism

(a) Immunofluorescence staining of xenograft tumor sections with or without co-implanted
EGFP+ CD11b+Gr-1+ IMCs. Increased expression of Ki67 and α-SMA in tumors that were
co-implanted with EGFP+ IMCs.
(b) Colonic adenomas from Hdc−/− mice treated with AOM + DSS showed greater α-SMA+
myofibroblasts in the stroma compared to wildtype mice. (The pictures in panel a and b
show representative data from five tumors in each group)
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(c) Q-RT-PCR results showed a significant increase in the RAGE ligand S100A8 and
MCP-1 expression in DSS–induced colitis tissue.
(d) Q-RT-PCR results showed a significant increase in the expression of RAGE ligands
S100A8 and S100A9 in colonic tumors of Hdc−/− mice compared to wildtype mice treated
with AOM + DSS.
(e) FACS analysis revealed a significant decrease in CD11b+Gr-1+ IMCs in the blood of
Rage−/− mice following AOM + DSS treatment (* P < 0.05; mean ± s.d. n = 5, each group).
(f) CT26 cancer cells suppressed Hdc-EGFP expression in BM-derived CD11b+Ly6G+
IMCs to a greater extent than control IEC-6 rat intestinal epithelial cells (* P < 0.05; mean ±
s.d. n = 3, each group).
(g) Hdc promoter methylation analysis by sodium bisulfate DNA sequencing. BM-derived
Hdc-EGFP+ CD11b+Ly6G+ IMCs were co-cultured with CT26 cancer cells for 48 hours and
DNA of IMCs was extracted for detection of DNA CpG methylation sites. Top: Bent arrow
shows the transcription start site and boxes represent the GC box and exon 1. Short vertical
lines across the horizontal line indicate CpG sites (−800 and +200 bp from the transcript
start site). Bottom: Filled and open circles represent methylated and unmethylated cytosine
residues respectively.
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